NDAORALTABLET
Approved
Mar 2023
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
5/8 — Partial
COMBOGESIC (acetaminophen and ibuprofen) by Aurobindo Pharma is cyclooxygenase inhibitors [moa]. Approved for minor aches, pains due to: headache toothache backache menstrual cramps muscular aches minor pain of arthritis. First approved in 2023.
Drug data last refreshed 10h ago · AI intelligence enriched 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COMBOGESIC is an oral tablet combining acetaminophen and ibuprofen, two cyclooxygenase inhibitors approved by the FDA on March 1, 2023. It treats minor aches and pains including headache, toothache, backache, menstrual cramps, muscular aches, and minor arthritis pain through dual analgesic and anti-inflammatory mechanisms. The fixed-dose combination leverages synergistic action of both NSAIDs to enhance efficacy in acute pain management.
Peak12.4 years to LOE
Product is in peak commercial phase post-approval; team expansion likely for field sales, managed care, and market penetration roles as market share solidifies.
Mechanism of Action
Cyclooxygenase Inhibitors
Pharmacologic Class:
Nonsteroidal Anti-inflammatory Drug
Worked on COMBOGESIC at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.